Stockreport

Jaguar's diarrhoea drug shows benefit in Phase III breast cancer subgroup [Yahoo! Finance]

Jaguar Health, Inc.  (JAGX) 
US:NASDAQ Investor Relations: jaguarhealth.gcs-web.com/investor-overview
PDF trial has shown statistically significant benefit in a prespecified subgroup of breast cancer patients. In July 2024, Jaguar announced the Phase III OnTarget trial (NC [Read more]